LINC00847通过准miR-455-3p/HDAC4轴来驱动胰腺癌的进展
Shunxin Hao1, Zhi Yao1, Yifeng Liu1
1Department of General Surgery, Wuhan University of Science and Technology Hospital, Wuhan, Hubei, China.
Archives of medical science : AMS
|July 25, 2024
概括
通过调节miR-455-3p/HDAC4轴,LINC00847促进胰腺癌 (PC) 的进展. 针对LINC00847可能为胰腺癌患者提供新的治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 生物化学 生物化学
背景情况:
- 胰腺癌 (PC) 是一种致命的恶性瘤,治疗选择有限.
- 了解驱动PC进展的分子机制对于开发有效治疗方法至关重要.
研究的目的:
- 研究LINC00847在胰腺癌中的作用.
- 为了阐明PC进展中的LINC00847/miR-455-3p/HDAC4信号通路.
主要方法:
- 定量实时PCR (RT-qPCR) 和西式涂抹来评估RNA和蛋白质水平.
- 细胞增殖,迁移和入侵试验 (殖民地形成,CCK-8,Transwell,划痕试验).
- 在体内小鼠异种移植模型和双露西法酶记者试验.
主要成果:
- 在PC细胞和组织中,LINC00847被上调,促进了增殖,迁移和入侵.
- LINC00847直接针对miR-455-3p,而miR-455-3p则针对HDAC4.4进行攻击.
- 过度表达HDAC4逆转了LINC00847对PC细胞的抑制作用.
结论:
- LINC00847通过miR-455-3p/HDAC4轴促进胰腺癌的进展.
- 这一途径代表了胰腺癌治疗的潜在治疗标.
相关概念视频
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
lncRNA - Long Non-coding RNAs
8.5K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.5K


